Alessandro Santin
Yale University · Gynecologic Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alessandro Santin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06028932 · A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsYale University · active not recruiting · Ovarian Carcinoma · principal investigator
- Ph2NCT02491099 · A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous CarcinomaYale University · recruiting · HER2/Neu+ Uterine Serous Carcinoma · principal investigator
- Ph2NCT00499031 · Cetuximab in Treating Patients With Persistent or Recurrent Cervical CancerGynecologic Oncology Group · completed · Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Integrated genomic analysis of racial disparities in endometrial cancerU01CA176067 · NCI · YALE UNIVERSITY · fiscal years 2014 to 2018 · $347,588 awarded in 2018Same name and institution; not confirmed by an ID
- CPE Peptide-Based Nanoparticles for the Diagnosis and Therapy of Chemotherapy ResR01CA154460 · NCI · YALE UNIVERSITY · fiscal years 2011 to 2015 · $345,488 awarded in 2015Same name and institution; not confirmed by an ID
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer by Administration of CPER01CA122728 · NCI · YALE UNIVERSITY · fiscal years 2008 to 2011 · $329,744 awarded in 2011Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Gynecologic Oncology GroupU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI Philip J. DiSaia · fiscal years 1985 to 2013Named on NCT00499031
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:58 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.N Engl J Med · 2022818 citationsRCR 55.4
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.Ann Oncol · 2019717 citationsRCR 25.0
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.N Engl J Med · 2019713 citationsRCR 26.7
- 404 citationsRCR 15.0
- 366 citationsRCR 18.9
- 252 citationsRCR 11.4
- 157 citationsRCR 6.3
- Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.J Clin Oncol · 2023144 citationsRCR 12.1
- Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).Gynecol Oncol · 2020129 citationsRCR 5.5
- 112 citationsRCR 2.5